Результаты поиска

Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer.

OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of FOLFOXIRI/FOLFOXIRI compared with mFOLFOX6/FOLFIRI in first-line and second-line chemotherapy for metastatic colorectal cancer (mCRC) from the perspectives of the USA and China, respectively, and provide a decision-making basis for clinical selection of these two regimens. DESIGN: The study used a decision-analytic Markov model to simulate the process of mCRC, including three distinct health states: progression-free survival, progressive disease and death. Clinical data were derived from the TRIBE2 trial.Costs and uti

Cost-Effectiveness of Once-Weekly Insulin Icodec versus Daily Basal Insulins in Chinese Adults with T2DM: A Treatment-Background Stratified Analysis.

OBJECTIVE: This study evaluated the long-term cost-effectiveness of once-weekly insulin icodec versus daily basal insulins in Chinese adults with type 2 diabetes mellitus (T2DM) across treatment backgrounds (insulin-naïve to basal-bolus users). METHODS: Using the UKPDS-OM2.1 model calibrated to ONWARDS trial data (1-5), we simulated lifetime outcomes over a 40-year horizon. Cost-utility analyses incorporated direct healthcare costs, complication utilities. Uncertainties were addressed using one-way and probabilistic sensitivity analyses. Scenario analyses explored pricing thresholds and adher

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.

OBJECTIVES: Enfortumab vedotin and pembrolizumab (EV-Pem) have recently been shown to improve the prognosis of patients with untreated locally advanced or metastatic urothelial carcinoma (la/mUC) in a randomised phase three clinical trial. This study aims to evaluate the cost-effectiveness of EV-Pem as a first-line treatment for patients with la/mUC. DESIGN: We developed a three-state Markov model to simulate the treatment pathways for patients with la/mUC. Costs associated with drugs, treatment monitoring, adverse event management and utility inputs were obtained from national cost databases

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan.

OBJECTIVE: To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment. METHODS: A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&…

Real-world cost-effectiveness analysis of thymoglobulin versus no induction therapy in kidney transplant recipients at low risk of graft loss.

BACKGROUND: A new induction therapy strategy of a single 3 mg/kg dose of rabbit antithymocyte globulin (r-ATG) showed a lower incidence of a … jection, cytomegalovirus infection/disease, death, graft loss, and retransplantation. RESULTS: The cost-effectiveness analysis in the first year revealed that the r-ATG group was more cost-effective, with an ICER of US$ 399.96 per avoided AR episode, an effectiveness gain of 0.01 year in graft survival and a total incremental cost of US$ 147.50. The 4- and 10-year analyses …

The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis.

OBJECTIVES: Non-Hispanic (NH) Black patients are disproportionally affected by nonmetastatic castration-resistant prostate cancer (nmCRPC). The objective was to quantify the health inequality impact of darolutamide + androgen deprivation therapy (ADT) relative to ADT for nmCRPC in the United States using a distributional cost-effectiveness analysis. METHODS: With a health economic model, quality-adjusted life years (QALYs) and costs were estimated for NH-White, NH-Black, NH-Asian, and Hispanic patients. Given the lifetime risk of nmCRPC and assuming equally distributed opportunity costs, the …

A Cost-effectiveness Analysis of Antibiotic Prophylaxis versus No Antibiotic Prophylaxis for Postoperative Infectious Complications for Hand-assisted Laparoscopic Donor Nephrectomy.

OBJECTIVES: Individuals who volunteer to undergo hand-assisted laparoscopic donor nephrectomy (HALDN) to help those needing renal transplants, face postoperative infection complications (POICs) risks for no corresponding clinical benefit. Prophylactic antibiotics often control POIC risk; however, there is no clear consensus on their use in HALDN. Considering the incidence of POICs, National Health Service (NHS) resource constraints, and antimicrobial stewardship priorities, a cost-effectiveness analysis (CEA) was conducted to evaluate the economic impact of prophylactic antibiotic use in HALDN…

Economic evaluation of [18F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis.

BACKGROUND: Primary hyperparathyroidism (PHPT) is characterized by persistent hypercalcemia caused by parathyroid adenomas. Preoperative localization of hyperfunctional parathyroids is crucial to optimize surgical outcomes. Current standard practice combines cervical ultrasound (CU), [99mTc]Tc-sestaMIBI SPECT scintigraphy (MIBI), and [18F]Fluorocholine PET/CT (PET) centered on the cervico-thoracic region. This study evaluates the cost-effectiveness of PET as a stand-alone first-line imaging strategy compared to CU + MIBI + PET and CU + PET strategies in the French healthcare system. METHODS:

Cost-effectiveness of office-based, magnetic resonance imaging-guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial.

BACKGROUND: As antimicrobial resistance increases, safer alternative approaches to prostate biopsy are needed. PREVENT was a multi-institutional, randomized controlled trial comparing transperineal (TP) biopsy without antibiotic prophylaxis versus transrectal (TR) biopsy with targeted prophylaxis. The authors conducted a secondary cost-effectiveness analysis of PREVENT. METHODS: The authors designed a Markov model with a simulated cohort of 1000 biopsied men. They assessed the short-term cost-effectiveness over a 2-week period, comparing relative costs in US dollars and utility measured in qu…

TB antigen-based skin tests and QFT-Plus for Mycobacterium tuberculosis infection diagnosis in Brazilian healthcare workers: a cost-effectiveness analysis.

This study aimed to analyze the cost-effectiveness of three tuberculosis (TB) antigen-based skin tests (TBST) (Diaskintest, C-TST, and Cy-TB) and QFT-Plus for TB infection diagnosis compared to the current standard of care, PPD Rt-23 tuberculin skin test (TST), among healthcare workers in Brazil. A state-transition Markov model was employed, simulating a cohort of healthcare workers (five annual cycles) for testing and treating TB infection with three months of weekly doses of rifapentine and isoniazid (3HP) under the Brazilian public health system perspective. Effects (TB disease averted) and

Vestibular Rehabilation in Multi Sclerosis: Randomized Controled Testing and Effectivity Analysis, сравнивая с адаптированным к учебникам Vestibular Rehabilation for Vestibulopathy.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Вестибульная дисфункция наблюдается в 30% в адрес 70% склероз (MS). ЦЕЛЬ: Сопоставление клинической и экономической эффективности специально разработанной программы реабилитации корпуса (ВР) с типовой программой, основанной на брошюре VR, для людей с MS с клиническими признаками эксгибибулопатии. МЕТОДЫ: Проверены на предмет наличия экстезибулопатии у людей с MS и симптомами вертиго и/или дисбаланса (n = 73). Seventy Число набранных участников было случайным 12-week :: типовая домашняя программа, основанная на брошюре, с поддержкой по телефону (n = 35) или a 12-week инди

Совпадение в аннотации оригинала
BACKGROUND: Vestibular dysfunction occurs in 30% to 70% of cases with multiple sclerosis (MS). OBJECTIVE: To compare the clinical and cost- … d group for vertigo symptom score, balance confidence, walking, and perceived impact of MS. Primary cost-effectiveness analysis showed customized VR to be less costly and more effective. However, removal of 2 cost outliers in sensitivity analysis resulted in a mean cost-per-QALY of £30 147. Customized VR was also cost-effective from a societal perspective. DISCUSSION: Impai …

Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study.

OBJECTIVES: Assessing the value of tumor-agnostic drugs (TAD) is challenging given the potential variability in treatment effects, trials with small sample sizes, different standards of care (SoC), and lack of comparative data from single-arm basket trials. Our study developed and applied novel methods to assess the value of pembrolizumab compared with SoC to inform coverage decisions. METHODS: We developed a partitioned survival model to evaluate the cost-utility of pembrolizumab for previously treated patients with 8 advanced or metastatic microsatellite instability-high or mismatch repair-

Secondary Prevention via Case Managers in Stroke Patients: A Cost-Effectiveness Analysis of Claims Data from German Statutory Health Insurance Providers.

Strokes remain a leading cause of death and disability worldwide. The STROKE OWL study evaluated a novel case management approach for patients with stroke (modified Rankin Scale 0-4) or transient ischemic attack (TIA) who received support across healthcare settings and secondary prevention training from case managers for one year. The primary aim of this quasi-experimental study was a reduction in stroke recurrence. Here, we report the results of a health economic analysis of the STROKE OWL study, conducted in accordance with CHEERS guidelines. The calculations were based on claims data of coo

Cost-effectiveness of surgical interventions in low-income and middle-income countries: a systematic review and critical analysis of recent evidence.

BACKGROUND: Cost-effectiveness evidence is a critical tool to support resource allocation decisions. There is growing recognition that the development of benefit packages for surgical care should be guided by such evidence, particularly in resource-constraint settings. METHODS: We conducted a systematic review of evidence (Medline, Embase, Global Health, EconLit and grey literature) on the cost-effectiveness of surgery across low-income and middle-income countries published between January 2013 and January 2023. We included studies with minor and major therapeutic surgeries and minimally inva

The Impact of Alternate Methodological and Structural Assumptions on Results of Cost-effectiveness Analysis: Empirical Evidence using Three Indian Economic Evaluations.

BackgroundDespite advancement in methods and application of economic evaluations (EEs), there are several uncertainties.ObjectivesTo assess the impact of alternate methodological and structural assumptions for four key principles of EE, on the results of cost-effectiveness analysis.Materials and methodsThree previously published model-based EEs were used: (1) Integrated Management of Neonatal and Childhood Illnesses (IMNCIs) intervention; (2) intervention for multiple myeloma, and (3) safety-engineered syringes (SES) intervention. A series of empirical analyses was undertaken to assess the imp…

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

BACKGROUND: The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments. However, this reimbursement policy should be preferably based on cost-effectiveness studies, among other criteria. This study performed a cost-effectiveness analysis of erenumab versus topiramate for the prophylactic treatment of episodic migraine (EM) and versus placebo for chronic migraine (CM). METHODS: A Markov model with a 10-year time horizon…

Моделирование использования первой линии Daratumumab для новых диагностированных, трансплантированных, не отвечающих установленным требованиям, множественных миелом: анализ эффективности затрат и рисков для работников системы здравоохранения.

СПРАВОЧНАЯ ИНФОРМАЦИЯ И ЦЕЛЬ: Это исследование было направлено на оценку эффективности затрат two Режимы, рассматриваемые в качестве стандарта для лечения недавно диагностированной, сносимой трансплантацией множественной миеломы в Сингапуре:1) Даратумумаб, линалидомид и дексаметасон и ()2Бортезомиб, линалидомид и дексаметасон. Кроме того, она направлена на изучение потенциальных стратегий регулирования неопределенности при принятии решений и снижения финансового риска.МЕТОДЫ: Анализ эффективности затрат с точки зрения системы здравоохранения был проведен с использованием модели раздельного выж

Совпадение в аннотации оригинала
BACKGROUND AND OBJECTIVE: This study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatme … xplore potential strategies to manage decision uncertainty and mitigate financial risk. METHODS: A cost-effectiveness analysis from the healthcare system perspective was conducted using a partitioned survival model to estimate lifetime costs and quality-adjusted life years (QALYs) associated with daratumumab-based treatment and the bortezomib-based regimen. The analysis use …

Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer Perspective.

INTRODUCTION: Type 2 diabetes (T2D) is a major cause of chronic kidney disease (CKD) in Japan, and there is an increasing treatment need for first- and second-line care in these patients. The addition of finerenone to current treatment modalities lowers the risk of CKD progression and cardiovascular events in patients with CKD and T2D from the Japanese payer perspective. This study investigated the cost-effectiveness analysis of adding finerenone to standard of care (SoC) versus SoC alone for the treatment of CKD in patients with T2D. METHODS: The FINE-CKD model validated to estimate the cost…

A cost-effectiveness analysis for high versus standard (low) dose caffeine for the treatment of apnea in neonatal intensive care unit.

OBJECTIVE: Preterm babies are prone to experiencing apnea of prematurity (AOP), mostly characterised by a pause in breathing lasting a minimum of 20 seconds. Recent literature supported higher maintenance doses of caffeine, indicating benefits. This study evaluated the cost-effectiveness of high maintenance dose (HD) versus low maintenance dose (LD) caffeine for AOP in neonates. METHODS: From the hospital perspective of Hamad Medical Corporation (HMC), Qatar, a cost-effectiveness decision-analytic model was constructed to follow the use of a HD maintenance caffeine of 20 mg/kg/dose versus a L

Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.

BACKGROUND: Traumatic haemorrhage is common after severe injury, leading to disability and death. Cryoprecipitate, a source of fibrinogen, m … he transfusion laboratory/blood bank. All analyses were performed on an intention-to-treat basis. A cost-effectiveness analysis was undertaken. SETTING: Twenty-five major trauma centres in the UK and one level 1 trauma centre in the USA. PARTICIPANTS: Adults who had traumatic haemorrhage following severe injury requiring activation of the major haemorrhage protocol and had …